KalVista FY2025: FDA approved EKTERLY; cash $220.6M; R&D down, G&A up

KalVista Pharmaceuticals, Inc.

FDA approved EKTERLY (sebetralstat) on July 7, 2025 as first oral on-demand HAE treatment; U.S. launch underway.
Cash and marketable securities $220.6M at April 30, 2025, providing runway into 2027.
R&D expenses $71.7M (down from $86.2M); G&A expenses $116.3M (up from $54.3M) driven by pre-commercial costs.
Entered licensing agreements for sebetralstat in Japan (Kaken, $11M upfront) and Canada (Pendopharm).
Six global regulatory submissions under review; new clinical data presented at EAACI, C1-INH, and EAC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.